Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7Carcinoma, Transitional Cell 7Ureteral Neoplasms 3Urologic Neoplasms 2Neoplasm Metastasis 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Adenocarcinoma of the Bladder 1

Interventions

Nivolumab 2sacituzumab govitecan 1relatlimab 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Specimen Handling 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cystoscopy 1Cisplatin 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Urothelial Carcinoma × enfortumab vedotin × 30 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡